文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

早产儿视网膜病变不同风险队列的再治疗率、时机与预测因素:玻璃体腔注射贝伐珠单抗与激光比较

Rates, Timing, and Predictors of Retreatment Across Risk-Cohorts in Retinopathy of Prematurity: Intravitreal Bevacizumab Injection Versus Laser.
PubMed 文献 · Am J Ophthalmol · 2026-06-27

这项回顾性比较临床研究纳入2017至2023年间接受首次治疗的181只治疗需求型早产儿视网膜病变患眼,比较初始激光与玻璃体腔注射贝伐珠单抗后的再治疗情况。结果显示贝伐珠单抗组3个月内再治疗及早期再治疗 odds 均低于激光组,再治疗时机更晚,且全部再治疗均发生于微早产或超早产儿。

要点

  • 贝伐珠单抗组3个月内再治疗 odds 低于激光组(OR 0.23,95%CI 0.06-0.82)。
  • 激光组早期再治疗比例21.5%,注射组1.7%,差异有统计学意义(P < .001)。
  • 全部再治疗均发生于胎龄<27周和/或体重<800克的微早产或超早产儿。

核心结论

  • 与激光相比,贝伐珠单抗与更低总体及早期再治疗相关,且在需要额外干预时时机更晚。
  • 侵袭性早产儿视网膜病变与更早再治疗相关,提示其可作为更严重疾病的标志。
  • 全部再治疗均发生于微早产或超早产儿,中低风险婴儿治疗后监测或可不必过于严格。

研究设计与样本

  • 患眼分为初始激光组(65只眼,35.9%)与初始贝伐珠单抗组(116只眼,64.1%)。
  • 主要观察指标为前3个月(0-90天)内再治疗,并分为早期(≤30天)与晚期(31-90天)。

主要发现

  • 16只眼(8.8%)需要早期再治疗,再治疗时中位矫正胎龄40.4周(IQR 38.44-43.3)。
  • 早期再治疗婴儿比例激光组为21.5%,注射组为1.7%,差异有统计学意义(P < .001)。
  • 17只眼(9.4%)需要晚期再治疗,中位矫正胎龄45.6周(IQR 43.7-47.4)。
  • 贝伐珠单抗组早期再治疗 odds 低于激光组(OR 0.08,95%CI 0.04-0.18);再治疗患眼中贝伐珠单抗组再治疗时矫正胎龄更晚(B=6.81,95%CI 4.68-8.93);侵袭性早产儿视网膜病变与更早再治疗相关(B=-7.72,95%CI -9.36至-6.10)。

临床怎么用

  • 对接受激光治疗的微早产或超早产儿应警惕早期再治疗风险,尤其在前30天内。
  • 贝伐珠单抗治疗后仍需随访,但再治疗时机可能更晚,需按矫正胎龄持续监测。
  • 合并侵袭性早产儿视网膜病变者再治疗可能更早,应加强随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize rates, timing, and predictors of retinopathy of prematurity (ROP) retreatment among infants treated with primary laser or intravitreal bevacizumab injection. DESIGN: Retrospective consecutive, comparative clinical study. PARTICIPANTS: Infants who underwent initial treatment for treatment-warranted ROP (TW-ROP) with either intravitreal bevacizumab or laser photocoagulation between 2017 and 2023. METHODS: Patients were stratified into two treatment groups: primary laser group vs primary bevacizumab group. MAIN OUTCOME MEASURES: Retreatment within the first 3 months (0-90 days) was assessed and classified as early (≤30 days) or late (31-90 days). RESULTS: Two hundred and thirty eight eyes of 122 infants were treated for ROP; of those, 181 (76.1%) eyes of 93 (76.2%) patients were included. There were 116 (64.1%) eyes in the bevacizumab group, and 65 (35.9%) eyes in the laser group. Thirty-three (18.2%) eyes-all micro- or nano-premature (<27 weeks GA and/or <800 grams)-required retreatment for TW-ROP. Sixteen (8.8%) required early retreatment at a median postmenstrual age (PMA) of 40.4 weeks (IQR, 38.44-43.3). There were differences in the proportion of early retreated infants (21.5% for laser vs 1.7% for injection, P < .001). Seventeen (9.4%) eyes required late retreatment. The median PMA at late retreatment was 45.6 weeks (IQR, 43.7-47.4). Infants in the bevacizumab group had lower odds of retreatment within three months than those with laser (OR, 0.23; 95% CI, 0.06-0.82). Similarly, patients in the bevacizumab group had lower odds of requiring early retreatment compared to those with laser (OR, 0.08; 95% CI, 0.04-0.18). Within eyes with retreatment, infants in the bevacizumab group had a later PMA at retreatment than those in the laser group (B = 6.81; 95% CI: 4.68-8.93). AROP was associated with earlier PMA at retreatment (B = -7.72; 95% CI, -9.36 to -6.10). CONCLUSION: In this study, early retreatment was low (8.8%), with most eyes initially treated with laser (21.5%) rather than bevacizumab (1.7%). Aggressive ROP was associated with earlier retreatment, highlighting its role as a marker of more severe disease. Compared to laser, bevacizumab was associated with lower overall and early retreatment, and delayed need for additional intervention when necessary. All retreatments occurred in micro- or nano-premature infants, suggesting that medium-to-low risk infants may require less strict post-treatment monitoring.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Altamirano F, Yuan M, Chaaya C, et al. Rates, Timing, and Predictors of Retreatment Across Risk-Cohorts in Retinopathy of Prematurity: Intravitreal Bevacizumab Injection Versus Laser. Am J Ophthalmol. 2026. PMID: 42364706. doi:10.1016/j.ajo.2026.06.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。